Clinical trial shows extended time to treatment failure with ianalumab and eltrombopag, suggesting enhanced efficacy over placebo.
Ianalumab plus eltrombopag led to a longer time to treatment failure than placebo plus eltrombopag. (Funded by Novartis; VAYHIT2 ClinicalTrials.gov number, NCT05653219.).
No takes yet. Share an insight, caveat, or question.
Cuker et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: